BIA Separations brings ‘sense of urgency’ to Zolgensma agreement
AveXis and BIA Separations announce an agreement for the commercial purification process of SMA gene therapy drug Zolgensma and further gene therapy candidates.
Archives for July 24, 2019
FDA approves the entrance of two biosimilars
US FDA gives approval to Samsung Bioepis’ Humira biosimilar and Pfizer’s Rituxan biosimilar, as the number of such medicines gaining entry onto the US market steadily increases.